243 related articles for article (PubMed ID: 25157773)
1. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer.
Speicher PJ; Ganapathi AM; Englum BR; Hartwig MG; Onaitis MW; D'Amico TA; Berry MF
J Thorac Oncol; 2014 Aug; 9(8):1195-201. PubMed ID: 25157773
[TBL] [Abstract][Full Text] [Related]
2. Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy.
Samson P; Puri V; Robinson C; Lockhart C; Carpenter D; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
Ann Thorac Surg; 2016 Jun; 101(6):2102-11. PubMed ID: 27083246
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.
Semenkovich TR; Panni RZ; Hudson JL; Thomas T; Elmore LC; Chang SH; Meyers BF; Kozower BD; Puri V
J Thorac Cardiovasc Surg; 2018 May; 155(5):2221-2230.e1. PubMed ID: 29428700
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
[TBL] [Abstract][Full Text] [Related]
6. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
7. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
[TBL] [Abstract][Full Text] [Related]
8. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
9. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer.
Ji KSY; Thomas SM; Roman SA; Czito B; Anderson KL; Frakes J; Adam MA; Sosa JA; Robinson TJ
J Gastrointest Surg; 2019 May; 23(5):885-894. PubMed ID: 30374818
[TBL] [Abstract][Full Text] [Related]
10. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
[TBL] [Abstract][Full Text] [Related]
11. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
[No Abstract] [Full Text] [Related]
12. The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.: a NCDB analysis.
Huang B; Chan EG; Pennathur A; Luketich JD; Zhang J
BMC Cancer; 2021 Dec; 21(1):1334. PubMed ID: 34911468
[TBL] [Abstract][Full Text] [Related]
13. Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions.
Erhunmwunsee L; Englum BR; Onaitis MW; D'Amico TA; Berry MF
Ann Surg Oncol; 2015 Mar; 22(3):1020-5. PubMed ID: 25234017
[TBL] [Abstract][Full Text] [Related]
14. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
[TBL] [Abstract][Full Text] [Related]
15. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
16. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
17. Management of Unresectable T4b Esophageal Cancer: Practice Patterns and Outcomes From the National Cancer Data Base.
Cushman TR; Shaaban SG; Moreno AC; Lin C; Verma V
Am J Clin Oncol; 2019 Feb; 42(2):154-159. PubMed ID: 30499838
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.
Samson P; Puri V; Lockhart AC; Robinson C; Broderick S; Patterson GA; Meyers B; Crabtree T
J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1725-1735. PubMed ID: 30054137
[TBL] [Abstract][Full Text] [Related]
19. Induction therapy before surgery improves survival in patients with clinical T3N0 esophageal cancer: a nationwide study in Taiwan.
Chao YK; Ku HY; Chen CY; Liu TW
Dis Esophagus; 2017 Dec; 30(12):1-7. PubMed ID: 28881891
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
